Study Examines the Impact of Legal Access to Medical Cannabis on Nonmedical Prescription Opioid Use
A recent study found that the legalization of medical cannabis in the United States was associated with a slight decrease in nonmedical prescription opioid use.
Citing the inconclusive current research on legalization of medical cannabis and its effect on nonmedical prescription opioid (NMPO) use, a recent study examined data from the 2004–2014 National Surveys on Drug Use and Health from adults ages 21 and older with NMPO use (1). The study titled, “Association Between Legal Access to Medical Cannabis and Frequency of Non-Medical Prescription Opioid Use Among U.S. Adults,” was published in the International Journal of Mental Health and Addiction on October 30th, 2023 (1). Researchers concluded that medical cannabis laws (MCL) were associated with a slight decrease in NMPO use (2).
After analyzing the data, researchers found that as a state legalized medical cannabis, there was a 0.5 to 1.5 percentage point decrease in regular to frequent NMPO use and a 2.1 percent point increase in occasional NMPO use (2). They also found that the most significant changes came only from those who had cannabis use disorder (CUD) (1). In those cases, frequent opioid use dropped 4.9 percentage points (3).
“The association of MCL with lower frequency of NMPO use was driven by individuals with cannabis use disorder, highlighting the importance of identifying tradeoffs of cannabis legalization as an intervention to reduce opioid-related harms,” the authors stated in the abstract (1).
In the face of the rising opioid-related deaths in the US, cannabis has been explored as a possible aid to reducing opioid addiction (2).
“There might be some benefits to allowing legal access to medical cannabis in the context of opioid-related harms,” stated Hillary Samples, lead author of the study (2). “However, from a policy perspective, there are much more effective interventions to address the ongoing overdose crisis, such as increasing access to treatment for opioid addiction.”
References
- Samples, H.; Levy, N. S.; Bruzelius, E.; Segura, L. E.; Mauro, P. M.; Boustead, A. E.; Mauro, C. M.; Martins, S. S. Association between legal access to medical cannabis and frequency of non-medical prescription opioid use among U.S. adults. International Journal of Mental Health and Addiction 2023 DOI: 10.1007/s11469-023-01191-y.
- Swenarton, N. States with legalized medical marijuana see decline in nonmedical opioid use https://www.rutgers.edu/news/states-legalized-medical-marijuana-see-decline-nonmedical-opioid-use (accessed Nov 15, 2023).
- Adlin, B. Medical marijuana legalization led to reduction in frequent use of nonmedical prescription opioids, study finds https://www.marijuanamoment.net/medical-marijuana-legalization-led-to-reduction-in-frequent-use-of-nonmedical-prescription-opioids-study-finds/ (accessed Nov 15, 2023).
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
